Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07088770 · ClinicalTrials.gov registry record · NA
TechMPower: Advancing HIV/SUD Care and Service Delivery for People in Re-entry
A NA study of HIV (Human Immunodeficiency Virus) and Substance Abuse Disorder, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 65
- Enrollment target
- 1
- Study location
NCT07088770: Completed NA study of HIV (Human Immunodeficiency Virus) and Substance Abuse Disorder, sponsored by Columbia University.
NCT07088770 is a NA study of HIV (Human Immunodeficiency Virus) and Substance Abuse Disorder that has completed, run by Columbia University. The registered enrollment target is 65 participants, roughly in line with the 69-participant average among 4 other HIV (Human Immunodeficiency Virus) trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07088770, a NA study of HIV (Human Immunodeficiency Virus) and Substance Abuse Disorder, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical study in one NY county is to pilot and refine implementation strategies aimed at improving delivery and uptake of evidence-based practices (EBPs) for HIV prevention/treatment and substance use disorder (SUD) care among incarcerated individuals approaching release with or at risk for HIV and SUD. The main questions it aims to answer are: 1. How feasible and acceptable are the TechMPower implementation strategies (community coalition workgroups, multidisciplinary implementation team with champion, and tech-mediated training/service delivery with peer navigation) in real-world carceral and reentry settings? 2. To what extent do these strategies improve delivery and uptake of HIV testing with self-testing (HST), pre-exposure prophylaxis (PrEP)/antiretroviral treatment (ART), medications for opioids use disorder (MOUD), and overdose education and naloxone distribution (OEND)? 3. What are the preliminary cost estimates for the implementation strategies and EBPs to inform the larger trial to follow in NY and NJ? 4. What are the preliminary impacts on individual-level outcomes such as HIV testing, linkage to care, and SUD treatment initiation? Our specific aims for the Phase I protocol presented here is conducted in one county (Ulster County) with a sample (n=50) of detained (prisoners) in their county jail are presented here: * R61 \| Aim 1: Evaluate \\ preliminary effectiveness of TechMPower, using mixed methods and a pre-/post-evaluation design, on increasing reach of the EBPs resulting in the following outcomes: (1) SUD and HIV screenings (pre-/post-release); and (2) linkage to SUD prevention/care (MOUD, OEND); and (3) linkage to HIV prevention/care (applying a status-neutral approach) with community service providers post-release. (Effectiveness). * R61 \| Aim 2: Identify how adoption/feasibility, implementation/fidelity and sustainability/maintenance of TechMPower may impact effectiveness of TechMPower outcomes as described in Aim 1 in on
Primary Outcome
This is to measure HIV testing (including self-testing) at jail. The number of participants that report in survey at least 1 testing will be tallied. Aggregate reporting on testing from facility will be captured for triangulation.
Conditions Studied
Interventions
- BEHAVIORAL Community Coalition CLS Workgroup/Network of Providers
- BEHAVIORAL Tech-mediated Training and Service Delivery
- BEHAVIORAL Multidisciplinary Implementation Team with Champion
- BEHAVIORAL Tech-mediated Peer Navigation Enhanced Case management (NCM)
Study Locations (1)
New York
- Ulster County Jail - Kingston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2024-11-22 |
| Est. Completion | 2025-09-30 |
| Phase | NA |
What the finished NCT07088770 record still lists
NCT07088770 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, roughly in line with the 69-participant average among 4 other HIV (Human Immunodeficiency Virus) trials with a reported enrollment target.
The record links to 2 conditions, with HIV (Human Immunodeficiency Virus) appearing as the primary indexed condition, and to 4 interventions - of which Community Coalition CLS Workgroup/Network of Providers is the first listed.
NCT07088770 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07088770 about?
NCT07088770 is a clinical study titled "TechMPower: Advancing HIV/SUD Care and Service Delivery for People in Re-entry". The goal of this clinical study in one NY county is to pilot and refine implementation strategies aimed at improving delivery and uptake of evidence-based practices (EBPs) for HIV prevention/treatment and substance use disorder (SUD) care among incarcerated individuals approaching release with or at...
What is the current status of trial NCT07088770?
This trial is currently completed. It is a NA study. The enrollment target is 65 participants. The study started on 2024-11-22. Estimated completion is 2025-09-30.
What conditions does trial NCT07088770 study?
This clinical trial studies the following conditions: HIV (Human Immunodeficiency Virus), Substance Abuse Disorder.
What interventions are being tested in trial NCT07088770?
The interventions under investigation include: Community Coalition CLS Workgroup/Network of Providers (BEHAVIORAL), Tech-mediated Training and Service Delivery (BEHAVIORAL), Multidisciplinary Implementation Team with Champion (BEHAVIORAL), Tech-mediated Peer Navigation Enhanced Case management (NCM) (BEHAVIORAL).
Who is sponsoring clinical trial NCT07088770?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07088770 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV (Human Immunodeficiency Virus)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI